North America Monoclonal Antibodies Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

No. of Pages: 169    |    Report Code: TIPRE00027987    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Monoclonal Antibodies Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Monoclonal Antibodies Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Monoclonal Antibodies Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Growing demand for targeted therapies
  • 5.1.3 Rising prevalence of chronic diseases
  • 5.1.4 Advancements in biopharmaceutical research
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Expansion in immunotherapy applications
  • 5.2.3 Development of biosimilar monoclonals
  • 5.2.4 Demand in autoimmune disease treatment
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Increased focus on personalized medicine
  • 5.3.3 Advancements in antibody-drug conjugates
  • 5.3.4 Growth in oncology monoclonal antibodies
5.4 Impact of Drivers and Restraints

6. North America Monoclonal Antibodies Market Regional Analysis

6.1 North America Monoclonal Antibodies Market Overview
6.2 North America Monoclonal Antibodies Market Revenue 2019-2028 (US$ Million)
6.3 North America Monoclonal Antibodies Market Forecast Analysis

7. North America Monoclonal Antibodies Market Analysis – by Source

7.1 Human
  • 7.1.1 Overview
  • 7.1.2 Human: North America Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Humanized
  • 7.2.1 Overview
  • 7.2.2 Humanized: North America Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Chimeric
  • 7.3.1 Overview
  • 7.3.2 Chimeric: North America Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Murine
  • 7.4.1 Overview
  • 7.4.2 Murine: North America Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Monoclonal Antibodies Market Analysis – by Production Method

8.1 In-Vitro
  • 8.1.1 Overview
  • 8.1.2 In-Vitro: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
8.2 In-Vivo
  • 8.2.1 Overview
  • 8.2.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Monoclonal Antibodies Market Analysis – by Indication

9.1 Cancer
  • 9.1.1 Overview
  • 9.1.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Autoimmune Diseases
  • 9.2.1 Overview
  • 9.2.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Infectious Diseases
  • 9.3.1 Overview
  • 9.3.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Inflammatory Diseases
  • 9.4.1 Overview
  • 9.4.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Microbial Diseases
  • 9.5.1 Overview
  • 9.5.2 In-Vivo: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Monoclonal Antibodies Market – North America Analysis

10.1 North America
  • 10.1.1 North America Monoclonal Antibodies Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 North America Monoclonal Antibodies Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Monoclonal Antibodies Market Breakdown, by Source
    • 10.1.1.1.2 US: North America Monoclonal Antibodies Market Breakdown, by Production Method
    • 10.1.1.1.3 US: North America Monoclonal Antibodies Market Breakdown, by Indication
  • 10.1.1.2 Canada: North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Monoclonal Antibodies Market Breakdown, by Source
    • 10.1.1.2.2 Canada: North America Monoclonal Antibodies Market Breakdown, by Production Method
    • 10.1.1.2.3 Canada: North America Monoclonal Antibodies Market Breakdown, by Indication
  • 10.1.1.3 Mexico : North America Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Monoclonal Antibodies Market Breakdown, by Source
    • 10.1.1.3.2 Mexico : North America Monoclonal Antibodies Market Breakdown, by Production Method
    • 10.1.1.3.3 Mexico : North America Monoclonal Antibodies Market Breakdown, by Indication

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Monoclonal Antibodies Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Novartis AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Pfizer Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Amgen Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 DAIICHI SANKYO COMPANY, LIMITED
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 AstraZeneca
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Eli Lilly and Company
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Bayer AG
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Company
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc.
  4. Amgen Inc
  5. DAIICHI SANKYO COMPANY, LIMITED
  6. F. Hoffmann-La Roche Ltd.
  7. AstraZeneca
  8. Eli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company
north-america-monoclonal-antibodies-market